23.06.2022 kl 16:19 3159

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting
Oslo, Norway, 9 March 2022

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on
CD37-targeted therapies for haematological cancers and immune diseases,
announces that an E-poster regarding Alpha37, entitled "Targeted alpha therapy
with [212]Pb-NNV003 in treatment of NHL", will be presented at the 2022 American
Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New
Orleans, USA.

The data in the E-poster show that a single injection of [212]Pb-NNV003, or
Alpha37, is safe and effective for the treatment of CD37-positive chronic
lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL) in mouse models.
Promising efficacy in both ibrutinib-resistant and ibrutinib-sensitive CLL
models was observed and treatment with Alpha37 was superior to both ibrutinib
and oblinutuzumab, confirming that further clinical development is warranted.
These data were previously presented at the company's R&D Day in November 2021.

Alpha37 has been developed as a targeted alpha radioimmunotherapy where the CD37
-specific antibody NNV003 is coupled to the alpha particle generating isotope
[212]Pb for the treatment of NHL and CLL. Despite the availability of current
treatments, most patients with these diseases inevitably relapse meaning that
there is a significant unmet need for new, alternative therapies.

Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: "The pre
-clinical data that we have amassed on Alpha37 is taking us closer towards our
goal of filing for an IND to begin human clinical testing. We are focussed on
high risk and/or ibrutinib resistant/refractory CLL as the entry indication but
believe there is a broader unmet need beyond this that Alpha37 may be able to
fulfil. We look forward to the further development of this next generation
targeted anti-CD37 alpha radio-immunoconjugate."

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.